katanin regulatory subunit B1 like 1 pseudogene 3Genealiases: []
Q-omics provides the consensus-scored KATNBL1P3 profile across patient tissues and cancer cell-line models. KATNBL1P3 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, KATNBL1P3 is differentially expressed in 6, with the highest sampling consensus in LUSC. Additionally, KATNBL1P3 RNA expression shows 16,168 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, LUSC, and GBM as cancer lineages where KATNBL1P3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KATNBL1P3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KATNBL1P3 survival associations across molecular data types. KATNBL1P3 RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KATNBL1P3 RNA expression–survival associations across cancer types. High KATNBL1P3 expression shows unfavorable associations in KIRC, COAD, UCS, ACC, LIHC and LUSC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for KATNBL1P3 RNA expression.
This table summarizes KATNBL1P3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for KATNBL1P3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KATNBL1P3 shows higher tumor expression in LUSC, BLCA, STAD, ESCA, HNSC and LUAD. The LUSC box plot shows higher KATNBL1P3 RNA expression in tumor versus normal tissue (log2 FC = +0.023, t-test p = .002).
This table shows molecular features associated with KATNBL1P3 in patient tissues and cancer cell lines. In patient samples, KATNBL1P3 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set.
